Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNJ1 | P48048 | 9/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.31 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.31 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.31 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18213669 | 0.88 | KCNH2 (0.39) | KCNJ1MEN1KMT2ACHEK1LIMK1 | |
| SCHEMBL12638572 | 0.76 | MEN1 (0.36) | KCNJ1MEN1KMT2ACHEK1LIMK1 | |
| SCHEMBL12638578 | 0.73 | CYP2C9 (0.37) | KCNJ1MEN1KMT2ATSHR | |
| SCHEMBL16897620 | 0.70 | CYP2A6 (0.45) | KCNJ1MEN1KMT2A | |
| SCHEMBL16869123 | 0.67 | KCNJ1 (0.35) | KCNJ1MEN1KMT2ATSHR | |
| SCHEMBL16866956 | 0.67 | KCNJ1 (0.35) | KCNJ1MEN1KMT2ATSHR | |
| SCHEMBL12638763 | 0.64 | KCNJ1 (0.35) | KCNJ1HPGDTSHR | |
| SCHEMBL25961076 | 0.62 | PTPN1 (0.46) | — | |
| SCHEMBL19105493 | 0.61 | KCNJ1 (0.41) | KCNJ1MEN1KMT2ACHEK1LIMK1 | |
| SCHEMBL24657652 | 0.59 | BACE1 (0.43) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180016263-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | MERCK SHARP & DOHME LLC | 2018-01-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180016263-A1 | INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL | KCNJ11, KCNJ1, SLC9A1 | KCNJ1 2/4885MEN1 354/4885KMT2A 1703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.